One-Year Outcome of Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injections for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy

One-Year Outcome of Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injections for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy

This study investigated one-year outcomes of treatment with one session of intravitreal recombinant tissue plasminogen activator, ranibizumab, and gas injections for submacular hemorrhage secondary to polypoidal choroidal vasculopathy (PCV). An extended study of a previous prospective trial of this...

Full description

Bibliographic Details
Main Authors: Yorihisa Kitagawa, Hiroyuki Shimada, Ryusaburo Mori, Koji Tanaka, Yu Wakatsuki, Hajime Onoe, Hiroyuki Kaneko, Yumiko Machida, Hiroyuki Nakashizuka
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Journal of Clinical Medicine
Subjects:
polypoidal choroidal vasculopathy
recombinant tissue plasminogen activator
ranibizumab
gas injections
aflibercept
central retinal thickness
Online Access:https://www.mdpi.com/2077-0383/11/8/2175

Similar Items

Similar Items